Clinical Trial Update: HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating a HER-2 pulsed dendritic cell vaccine to prevent recurrence of invasive breast cancer following…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HER-2 pulsed dendritic cell vaccine (HER-2 pulsed dendritic cell vaccine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED